Cornea

Two optical treatment modalities can slow pediatric myopia progression without the need for pharmacologic intervention, ie, spectacle lenses incorporating highly aspherical lenslets (HAL) and orthokeratology (ortho-k) contact lenses. Both treatments are based on the same underlying theory that peripheral retinal defocus is a growth signal for axial elongation‚ but the treatments focus on different structures of the visual system, one through a manufactured spectacle lens surface (HAL) and the other through temporary corneal reshaping (ortho-k).

A retrospective study of nearly 1,000 patients found epithelial resolution with serial decellularized basement membrane graft use in subclinical to Stage 1 disease.

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

The FDA issued a recall notice for an eye drop designed to relieve ocular redness, itching, burning, and watery eyes. The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting

Rare retinal diseases initially were the primary targets of gene therapy, but that is no longer the case. The focus has expanded beyond those to also include more common, chronic diseases such as diabetic macular edema and wet age-related macular degeneration. During the first half of 2026, that trend was evident.

The FDA issued a nationwide recall of a steroid eye drop.

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.

Length and width, not thickness, emerge as key drivers of higher-order aberrations.

Real-world data support EndoArt as donor-independent option in high-risk patients

Researchers identify microbial shifts tied to corneal disease history

Ophthalmology Times® On Air

A sutureless amniotic membrane matrix achieved faster healing and lower costs than standard PED care in a two-centre NHS audit.

A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.

Immediate flushing of the eye can significantly reduce long-term damage after chemical exposure

After accounting for key factors like eye length, researchers found no meaningful differences in corneal biomechanics between primary open-angle and primary angle-closure glaucoma.

A case report describes image-guided surgical excision combined with adjunctive cryotherapy and a single anterior chamber methotrexate injection, with no recurrence at 10 months.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

Examining the physiologic limits can help identify when its usage may be ineffective

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.